Evidence map›Paper›PMID 23778314›Full record

ArticleHuman vaccines & immunotherapeutics2013

Naturally occurring IgG antibody levels to the Staphylococcus aureus protein IsdB in humans.

Julie K Zorman, Mark Esser, Michael Raedler, Barry N Kreiswirth, Dlawer A A Ala'Aldeen, Nicholas Kartsonis, Steven S Smugar, Annaliesa S Anderson, Tessie McNeely, Jean Marie Arduino

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. HumanmBio · 2019
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Where does a Staphylococcus aureus vaccine stand?Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2014
    Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Julie K ZormanMerck Sharp & Dohme Corp.; Whitehouse Station, NJ USA.
Mark Esser
Michael Raedler
Barry N Kreiswirth
Dlawer A A Ala'Aldeen
Nicholas Kartsonis
Steven S Smugar
Annaliesa S Anderson
Tessie McNeely
Jean Marie Arduino
MSD K.K. (Japan) · JPMerck & Co., Inc., Rahway, NJ, USA (United States) · USNewark Academy · USUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Staphylococcus aureus is a well-recognized, clinically important cause of nosocomial infections, and as such, a vaccine to prevent S. aureus infections would be an important achievement. A Phase IIB/III study of V710, a vaccine containing iron-regulated surface determinant B (IsdB), demonstrated significant sero-conversion rates in cardiovascular surgery patients following a single pre-surgery immunization. However, the vaccine was not efficacious in preventing bacteremia or deep sternal wound infection post-surgery, thus raising the possibility that IsdB might not be available for immune recognition during infection. The purpose of the work described herein was to evaluate and quantify the naturally occurring anti-IsdB levels at baseline and over time during infection, to understand whether IsdB is expressed during a S. aureus infection in hospitalized non-vaccinated patients. We evaluated baseline and follow-up titers in 3 populations: (1) healthy subjects, (2) hospitalized patients with non-S. aureus infections, and (3) hospitalized patients with S. aureus infections. Baseline anti-IsdB levels generally overlapped between the 3 groups, but were highly variable within each group. In healthy subjects, baseline and follow-up levels were highly correlated (Spearman's rho = 0.93), and the geometric mean fold-rise (GMFR) in anti-IsdB levels between study entry and last value was 0.9-fold (95% confidence interval (CI): 0.8 to 1.0 ; p = 0.09), showing no trend over time. The convalescent GMFR in anti-IsdB levels from baseline was 1.7-fold (95% CI: 1.3 to 2.2, p = 0.0008) during S. aureus infection, significantly different from the 1.0-fold GMFR (95% CI: 0.9-1.2, p = 0.60) in non-S. aureus infection, p = 0.005. Additionally, S. aureus isolates (51) obtained from the hospitalized patient group expressed the IsdB protein in vitro. Collectively, these data suggest that IsdB expression levels rise substantially following infection with S. aureus, but not with other pathogens, and IsdB is likely well-conserved across S. aureus strains.

Indexed as

AdultAgedAged, 80 and overAntibodies, BacterialCation Transport ProteinsFemaleHealthy VolunteersHumansImmunoglobulin GInpatientsMaleMiddle AgedStaphylococcal InfectionsYoung AdultAntibodies, BacterialCation Transport ProteinsImmunoglobulin GIsdB protein, Staphylococcus aureusantibody levelshealthy subjectshospitalized patientsIsdBS. aureusinfection

Identifiers

PMID23778314
PMCPMC3906349
OpenAlexW2013588352

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.